Alexza Pharmaceuticals, Inc.  

(Public, OTCMKTS:ALXA)   Watch this stock  
Find more results for NASDAQ:ALXA
- Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -1.22
Shares 21.75M
Beta     -
Inst. own 26%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -466.94% -424.00%
Operating margin -222.78% -796.34%
EBITD margin - -736.63%
Return on average assets -106.54% -55.87%
Return on average equity - -
Employees 27 -
CDP Score - -


2091 Stierlin Ct
MOUNTAIN VIEW, CA 94043-4655
United States - Map
+1-650-9447000 (Phone)
+1-650-9447999 (Fax)

Website links


Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company's product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.